No Handouts for Drug Advertisements Act

The No Handouts for Drug Advertisements Act would amend the Internal Revenue Code to prohibit tax deductions for expenses related to direct-to-consumer advertising of certain prescription and compounded drugs. It affects pharmaceutical companies and entities that sponsor or own outsourcing facilities for such drugs, disallowing deductions for advertising disseminated via television, radio, internet, social media, billboards, and direct mail—though ads in medical journals and periodicals would remain deductible. The change would apply to expenses incurred after the bill’s enactment, aiming to reduce taxpayer-subsidized marketing of drugs to the general public.

No official summary is available here. This one was written by AI from the bill’s text.